MedTrace Logo

Daily REmote Ischaemic Conditioning Following Acute Myocardial Infarction

NCT01664611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-01-31

No results posted yet for this study

Summary

Remote ischaemic conditioning (RIC) is known to reduce infarct size post MI when used in the peri/immediate post infarct period. However little is known as to the effect of repeated remote conditioning post-MI (Myocardial Infarction) on not only infarct size, but also on ventricular remodeling and ultimately cardiac failure. In this phase II first in man trial, the investigators intend to carry out daily remote ischaemic conditioning in post MI patients. The principal hypothesis is that RIC applied on a daily basis for 4 weeks following a heart attack improves the ejection fraction at 4 months as assessed by cardiac magnetic resonance imaging.

Conditions

  • Post Myocardial Infarction

Interventions

PROCEDURE

Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm

Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.

PROCEDURE

Sham conditioning

Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury

Sponsors & Collaborators

  • University Hospitals, Leicester

    collaborator OTHER

  • Freemasons' Medical Research Funding

    collaborator UNKNOWN

  • University of Leicester

    lead OTHER

Principal Investigators

  • Nilesh Samani, FRCP, MD, MBChB, BSc · University of Leicester

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-26
Primary Completion
2016-10-30
Completion
2016-10-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01664611 on ClinicalTrials.gov